This site is intended for US healthcare professionals only
  • For Patients and Caregivers
  • Important Safety Information
  • Prescribing Information
  • Sign Up
ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension for intravenous infusion
  • About ZOLGENSMA
    • Efficacy
      • STR1VE Trial
      • START Trial
      • START Long-Term Follow-Up
      • SPR1NT Trial
    • SafetyView Important Safety Information
    • Dosing and InfusionPreparing and infusing ZOLGENSMA
    • Mechanism of ActionSee how ZOLGENSMA works
    • Patient ProfilesWatch family stories
  • Steps to treatment
    • Before TreatmentIdentifying eligible patients
    • Prepare for InfusionGetting ready for infusion day
    • After TreatmentEssential post-infusion monitoring and management
  • Understand SMA
  • Resources
Sign Up
  • About ZOLGENSMA
    • Efficacy
      • STR1VE Trial
      • START Trial
      • START Long-Term Follow-Up
      • SPR1NT Trial
    • SafetyView Important Safety Information
    • Dosing and InfusionPreparing and infusing ZOLGENSMA
    • Mechanism of ActionSee how ZOLGENSMA works
    • Patient ProfilesWatch family stories
  • Steps to treatment
    • Before TreatmentIdentifying eligible patients
    • Prepare for InfusionGetting ready for infusion day
    • After TreatmentEssential post-infusion monitoring and management
  • Understand SMA
  • Resources
For Patients and Caregivers

Site Map

  • About ZOLGENSMA
    • Efficacy
      • STR1VE Trial
      • START Trial
      • START Long-Term Follow-Up
      • SPR1NT Trial
    • SafetyView Important Safety Information
    • Dosing and InfusionPreparing and infusing ZOLGENSMA
    • Mechanism of ActionSee how ZOLGENSMA works
    • Patient ProfilesWatch family stories
  • Steps to treatment
    • Before TreatmentIdentifying eligible patients
    • Prepare for InfusionGetting ready for infusion day
    • After TreatmentEssential post-infusion monitoring and management
  • Understand SMA
  • Resources

Indication

ZOLGENSMA is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

Limitations of Use
The safety and effectiveness of repeat administration or the use in patients with advanced SMA (e.g., complete paralysis of limbs, permanent ventilator dependence) has not been evaluated with ZOLGENSMA.

Important Safety Information

BOXED WARNING: Acute Serious Liver Injury

Acute serious liver injury and elevated aminotransferases can occur with ZOLGENSMA. Patients with pre-existing liver impairment may be at higher risk. Prior to infusion, assess liver function of all patients by clinical examination and laboratory testing (e.g., hepatic aminotransferases [aspartate aminotransferase (AST) and alanine aminotransferase (ALT)], total bilirubin, and prothrombin time). Administer a systemic corticosteroid to all patients before and after ZOLGENSMA infusion. Continue to monitor liver function for at least 3 months after infusion.

WARNINGS AND PRECAUTIONS

Thrombocytopenia
Transient decreases in platelet counts, some of which met the criteria for thrombocytopenia, were observed at different time points after ZOLGENSMA infusion. Monitor platelet counts before ZOLGENSMA infusion and on a regular basis for at least 3 months afterwards.

Thrombotic Microangiopathy
Cases of thrombotic microangiopathy (TMA) were reported approximately 1 week after ZOLGENSMA infusion. Obtain baseline creatinine and complete blood count before ZOLGENSMA infusion. Following infusion, monitor for thrombocytopenia as well as other signs and symptoms of TMA. Consult a pediatric hematologist and/or pediatric nephrologist immediately to manage if clinically indicated.

Elevated Troponin-I
Transient increases in cardiac troponin-I levels were observed following ZOLGENSMA infusion. Monitor troponin-I before ZOLGENSMA infusion and on a regular basis for at least 3 months afterwards.

ADVERSE REACTIONS

The most commonly observed adverse reactions (incidence ≥5%) in clinical studies were elevated aminotransferases and vomiting.

Please click here for Full Prescribing Information.

  • PRIVACY POLICY
  • TERMS OF USE
  • SITE MAP
  • CONTACT US

This website may use cookies to improve the site and your experience. See how Novartis Gene Therapies collects, uses, and shares your personal information in our Privacy Policy. 

This site is intended for US healthcare professionals only.

© 2021 Novartis Gene Therapies, Inc.
Bannockburn, IL 60015


03/2021  US-ZOL-20-0069 V2

You are now leaving
ZOLGENSMA-hcp.com:

Novartis Gene Therapies provides links to third-party sites as a convenience and is not responsible for the content of these sites.

Would you like to continue?
Click "No" to keep browsing ZOLGENSMA-hcp.com.

Yes